Rhythm Pharmaceuticals (RYTM) Current Assets (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Current Assets data on file, last reported at $430.1 million in Q1 2026.

• Current Assets for Q1 2026 came in at $430.1 million, up 16.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $430.1 million (up 16.46% YoY), and the FY2025 annual result was $466.9 million, up 24.78% from the prior year.
• Current Assets eased to $430.1 million in Q1 2026 per RYTM's latest filing, from $466.9 million in the prior quarter.
• Over five years, Current Assets peaked at $494.8 million in Q3 2025 and troughed at $235.8 million in Q1 2024.
• A 5-year average of $346.3 million and a median of $354.2 million in 2022 frame the typical range for Current Assets.
• The sharpest annual moves came in 2022 and 2025: Current Assets tumbled 38.5% in 2022, then soared 56.64% in 2025.
• A 5-year view of Current Assets shows it stood at $354.2 million in 2022, then declined by 12.98% to $308.3 million in 2023, then gained by 21.39% to $374.2 million in 2024, then advanced by 24.78% to $466.9 million in 2025, then fell by 7.89% to $430.1 million in 2026.
• Business Quant data shows RYTM's Current Assets at $430.1 million in Q1 2026, $466.9 million in Q4 2025, and $494.8 million in Q3 2025.